Health
LoDoCo2: Added Steam for Colchicine as Secondary Prevention – Medscape
The benefits emerged early and continued to accrue through the trial, with no suggestion of attenuation during up to 5 years of treatment.
The anti-inflammatory drug colchicine picked up new support as secondary prevention in chronic coronary disease, cutting the risk of cardiovascular events by one third when added to standard prevention therapies in the double-blind LoDoCo2 study.
Across a median follow up of 29 months in more than 5000 patients, almost 1 in 10 patients assigned to placebo experienced the primary endpoint of cardiovascular (CV) death, myocardial infarction (MI), ischemic stroke, or ischemia-driven coronary revas…
-
Noosa News11 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News12 hours agoMotorcyclist dies in crash with truck
-
Noosa News13 hours agoSomerville House investigating after teachers’ dossier on students leaked
-
General18 hours agoSmall-town cleaner finds himself in legal battle with EnduroShield over product packaging